Thoracic Oncology Department 1

Department 1 of Thoracic Oncology at the Second Affiliated Hospital of Dalian Medical University is a lung cancer subspecialty that primarily treats patients with thoracic tumors, is a national-level key oncology specialty as well as a key oncology specialty of Liaoning Province and Dalian City, and enjoys a high reputation both within and outside the province. At present, in the diagnosis and treatment of intermediate- and advanced-stage lung cancer, it has attained a regionally leading and nationally first-class position. It is an institutional member of the Multinational Association of Supportive Care in Cancer (MASCC), an institutional member of the International Association for the Study of Lung Cancer (IASLC), an institution holding a national vice-chair position in the Professional Committee of Molecular Oncology and Immunotherapy of the Chinese Research Hospital Association, and an institution holding a national vice-chair position in the Professional Committee of Oncology Science Popularization of the Medical Science Popularization Branch of the Chinese Medical Doctor Association.

The department emphasizes precision medicine, achieving precision diagnosis and precision treatment on the basis of standardized and individualized approaches. The field of lung cancer has now entered a phase of rapid development. Department physicians seize opportunities for exchange and learning at international academic conferences on lung cancer and, drawing on their own experience, work with colleagues in China to formulate Chinese versions of guidelines and consensus statements for the diagnosis and treatment of lung cancer. While strengthening their clinical fundamentals, young physicians actively participate in the department's research and teaching activities; at the daily morning reading session, young physicians lecture in rotation, critique one another, and the department director provides a summary. After 7 years of perseverance, many clinical and research problems have been readily resolved, and the physicians are thoroughly familiar with new developments; the department currently has 6 physicians, including 2 chief physicians, 1 deputy chief physician, and 3 attending physicians; 2 hold doctoral degrees, 1 is currently pursuing a doctorate, and 3 hold master's degrees. There is 1 doctoral supervisor in clinical oncology and 1 master's supervisor.

The department routinely participates in multidisciplinary consultations (MDT) within the hospital and at the provincial and national levels. In addition, years of collaboration with leading research institutions in China and abroad, including Mayo Clinic in the United States, the University of North Carolina in the United States, the Cancer Hospital of the Chinese Academy of Medical Sciences, and the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences, have been highly rewarding for the department. It has led and participated in multiple international, national, provincial, and municipal research projects; served as editor-in-chief of 2 national-level planned textbooks and 4 books; published more than 30 SCI articles, with a cumulative impact factor of more than 150 points; and, as the first principal contributor, received 5 provincial- and municipal-level scientific research awards. Each year, it hosts multiple high-level academic conferences, which, while honing young physicians, enable the department to accumulate valuable experience for its development, enhance the specialty's regional influence, and increase the visibility of the Second Affiliated Hospital of Dalian Medical University in the field of lung cancer.

This department has extensive clinical experience in standardized and individualized multidisciplinary comprehensive treatment of thoracic tumors, especially lung cancer, pleural mesothelioma, and mediastinal tumors (thymic tumors); it specializes in etiological research on lung cancer and precision screening of high-risk populations; it performs precise genotyping of patients with lung cancer to achieve precision diagnosis and treatment; it precisely selects suitable candidates for lung cancer immunotherapy and promptly manages adverse reactions; it conducts clinical research on novel drugs for lung cancer and keeps abreast of new technologies and therapies in the field of lung cancer treatment; 2 of its members are members of the pulmonary nodule MDT expert group and provide precise diagnosis and treatment for pulmonary nodules; and it integrates Chinese and Western medicine to provide palliative and supportive treatment for advanced lung cancer.

The department has 16 nurses, including 1 wound, ostomy, and continence specialist nurse, 2 VTE specialist nurses, 2 PICC specialist nurses, and 3 pain specialist nurses; 5 nurses in total have obtained GCP certificates, making this a highly professional and technically skilled nursing team.

Department 1 of Thoracic Oncology will always uphold the departmental development philosophy of “breathing with the hospital and advancing together,” continue to work hard and pursue innovative development, and strive to secure the greatest possible survival benefit for patients with thoracic tumors!